Oncology · HER2-Positive Breast Carcinoma

Moving Forward: Life as a Survivor

At a Glance

After HER2-positive breast cancer treatment, survivorship care emphasizes personalized follow-up, mammography, lasting side-effect management, heart monitoring when needed, and reporting new symptoms; routine whole-body scans are generally not recommended for asymptomatic early-stage survivors.

The transition from active treatment to “life after cancer” is often a time of mixed emotions. While there is a sense of relief, many patients also feel a new kind of vulnerability. Survivorship is a dedicated phase of care focused on managing long-term side effects, protecting your emotional health, and remaining vigilant through evidence-based monitoring ^[1] ^[2].

Managing the Psychological Toll: “Scanxiety”

One of the most common challenges in survivorship is Fear of Cancer Recurrence (FCR). This fear often spikes around the time of follow-up appointments or imaging, a phenomenon many patients call scanxiety ^[3].

A Real Experience: Fear of recurrence is incredibly common; a large proportion of survivors report experiencing meaningful fear that persists for years after diagnosis ^[3] ^[4].
Coping Strategies: FCR is distinct from general anxiety and often requires its own tools ^[5]. Cognitive-behavioral therapy (CBT), mindfulness, and support groups have been shown to help reduce the intensity of these fears ^[6] ^[7]. Support from psycho-oncology is appropriate at any point in your care.

Long-Term Quality of Life

The modern drugs that target HER2 are powerful, and their effects can linger.

Physical Recovery: Fatigue and reduced muscle strength are frequently reported. Participating in structured exercise or physical therapy has been shown to improve fitness and quality of life after HER2 therapy ^[8] ^[9].
Neuropathy and Brain Fog: Chemotherapy drugs can cause long-term numbness or tingling in the hands and feet (neuropathy) or subtle changes in memory and concentration ^[10].
Heart Health: While most heart-related side effects from HER2 drugs are reversible, a small percentage of patients may experience long-term heart issues, particularly those who received anthracycline chemotherapies or have other cardiovascular risk factors ^[11] ^[12]. Your care plan should include an individualized schedule for cardiac monitoring ^[13].

Understanding Recurrence Risk in Early-Stage Disease

The prognosis for early-stage HER2-positive disease has vastly improved, but your team will continue to monitor you because the risk of recurrence varies based on individual factors like tumor size, node status, and response to neoadjuvant treatment.

Timing of Risk: For HER2-positive cancer that is also hormone-receptor positive, there is a persistent risk of the cancer returning later. Completing your full course of hormone-blocking therapy is critical ^[14].
Response-Adapted Risk: Patients with residual invasive disease after neoadjuvant treatment have a higher baseline risk, but utilizing adjuvant treatments like T-DM1 (Kadcyla) significantly mitigates that risk ^[15] ^[16].
Evidence-Based Surveillance: Current guidelines emphasize that routine full-body scans are generally not recommended for asymptomatic early-stage survivors ^[17] ^[18]. Instead, follow-up focused on physical exams and mammography is the standard of care ^[19]. However, never ignore new symptoms—surveillance does not mean ignoring changes in your body.

Living Chronically with Advanced Disease

For those with metastatic disease, survivorship focuses on balancing the side effects of continuous treatment with the goal of living a full and active life. Modern treatments have turned what was once a rapidly progressive disease into a condition that can often be managed over a prolonged period ^[20]. Your care team should focus on “person-centered” care, ensuring your treatment plan aligns with your personal priorities ^[2] ^[21].

Common questions in this guide

What follow-up care is usually recommended after treatment for HER2-positive breast cancer?

Your schedule depends on your original stage, tumor size, lymph node status, response to treatment before surgery, and treatments you received. For people with early-stage disease who have no symptoms, follow-up usually emphasizes visits, physical exams, and mammography rather than routine full-body scans. Your oncology team should give you a personalized survivorship care plan.

Is scanxiety or fear of recurrence normal after HER2-positive breast cancer?

Fear of recurrence is common and can intensify before appointments or imaging, even years after treatment. If it affects sleep or daily activities, cognitive-behavioral therapy, mindfulness, support groups, or psycho-oncology can help. Tell your care team rather than managing it alone.

What lasting effects can HER2-positive breast cancer treatment cause?

Some people have ongoing fatigue, reduced muscle strength, numbness or tingling in their hands and feet, or changes in memory and concentration. Exercise programs, physical therapy, and rehabilitation may improve fitness and quality of life. Report persistent or new symptoms so your team can assess them.

Do I need heart monitoring after HER2 treatment ends?

Many heart-related effects of HER2-targeted drugs improve or reverse, but a small number of people have longer-term heart problems. Monitoring is individualized based on your treatments, including any anthracycline chemotherapy, and cardiovascular risk factors. Ask your oncology team how long you need heart checks and which symptoms should prompt a call.

What does residual disease after treatment before surgery mean for recurrence risk?

Residual invasive disease means invasive cancer remained after treatment given before surgery, and it is associated with a higher baseline risk of recurrence. For some patients, additional treatment such as adjuvant T-DM1 (Kadcyla) can substantially reduce that risk. Your team can explain how your surgical findings affect your plan.

If my HER2-positive cancer is hormone-receptor positive, will I need hormone therapy?

Hormone-blocking therapy may be recommended when a HER2-positive breast cancer is also hormone-receptor positive, and completing the planned course can lower the risk of the cancer returning. The benefits should be weighed against side effects such as bone or sexual health concerns. Ask your oncology team how to manage side effects without stopping treatment on your own.

How is survivorship managed when HER2-positive breast cancer is metastatic?

For metastatic disease, survivorship often means living with ongoing treatment while managing side effects and maintaining daily life. Care is person-centered, so the plan should reflect your priorities, activities, and quality-of-life goals. Tell your team which benefits and burdens matter most to you.

Curated prompts to bring to your next appointment.

1.Given my original stage and response to treatment, what is my specific 'surveillance' schedule for the next five years?
2.I am experiencing (fatigue/neuropathy/brain fog)—are there rehabilitation or survivorship programs at this center that can help?
3.How long will I continue to have my heart function monitored now that my primary HER2 treatment is finished?
4.If my cancer was also HR-positive, how do we balance the benefits of long-term hormone therapy with the side effects I am experiencing (e.g., bone health, sexual health)?
5.Who should be my main point of contact for new symptoms—my oncologist or my primary care doctor?

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Key takeaways

Survivorship care after HER2-positive breast cancer includes personalized follow-up, physical exams, mammography, and attention to new symptoms; routine full-body scans are generally not recommended for asymptomatic early-stage survivors.
Fatigue, muscle weakness, neuropathy, and brain fog can persist after treatment and may improve with exercise, physical therapy, or rehabilitation.
Most heart-related effects from HER2-targeted drugs are reversible, but some patients need individualized cardiac monitoring, especially after anthracyclines or with cardiovascular risk factors.
Fear of recurrence or scanxiety is common and can be helped with cognitive-behavioral therapy, mindfulness, support groups, and psycho-oncology.
For hormone-receptor-positive or metastatic disease, long-term hormone therapy or continuous treatment may be part of care and should be balanced with goals and side effects.

References (21)

1
Expert consensus on disease-based long-term follow-up care plans for childhood cancer survivors.
Cai JY, Pui CH, Ju XL, et al.
World journal of pediatrics : WJP 2025; (21(12)):1204-1217 doi:10.1007/s12519-025-00989-1.
PMID: 41165934
2
Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations.
Hart NH, Nekhlyudov L, Smith TJ, et al.
JCO oncology practice 2024; (20(9)):1160-1172 doi:10.1200/OP.23.00716.
PMID: 38684036
3
Scanxiety and Fear of Recurrence in Young Adult Female Breast and Gynaecological Cancer Survivors: Investigating Shared Mechanisms.
Patel DS, Webster SN, Dowling EJ, et al.
Psycho-oncology 2024; (33(12)):e70050 doi:10.1002/pon.70050.
PMID: 39694862
4
Fear of Cancer Recurrence and Its Negative Impact on Health-Related Quality of Life in Long-term Breast Cancer Survivors.
Tran TXM, Jung SY, Lee EG, et al.
Cancer research and treatment 2022; (54(4)):1065-1073 doi:10.4143/crt.2021.835.
PMID: 34883553
5
Network connectivity between fear of cancer recurrence, anxiety, and depression in breast cancer patients.
Yang Y, Sun H, Luo X, et al.
Journal of affective disorders 2022; (309()):358-367 doi:10.1016/j.jad.2022.04.119.
PMID: 35472477
6
The effect of psychological interventions on fear of cancer recurrence in breast cancer survivors: A systematic review and meta-analysis.
Lyu MM, Siah RC, Lam ASL, Cheng KKF
Journal of advanced nursing 2022; (78(10)):3069-3082 doi:10.1111/jan.15321.
PMID: 35696315
7
Mindfulness-Based Cognitive Therapy for Psychological Distress, Fear of Cancer Recurrence, Fatigue, Spiritual Well-Being, and Quality of Life in Patients With Breast Cancer-A Randomized Controlled Trial.
Park S, Sato Y, Takita Y, et al.
Journal of pain and symptom management 2020; (60(2)):381-389 doi:10.1016/j.jpainsymman.2020.02.017.
PMID: 32105790
8
Self-Reported Physical Activity, QoL, Cardiac Function, and Cardiorespiratory Fitness in Women With HER2+ Breast Cancer.
Peck SS, Esmaeilzadeh M, Rankin K, et al.
JACC. CardioOncology 2022; (4(3)):387-400 doi:10.1016/j.jaccao.2022.06.006.
PMID: 36213351
9
Lack of Needs Assessment in Cancer Survivorship Care and Rehabilitation in Hospitals and Primary Care Settings.
Handberg C, Jensen CM, Maribo T
Journal of clinical medicine research 2017; (9(10)):864-871 doi:10.14740/jocmr3160w.
PMID: 28912923
10
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.
Tolaney SM, Tayob N, Dang C, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2021; (39(21)):2375-2385 doi:10.1200/JCO.20.03398.
PMID: 34077270
11
Real-World Cardiotoxicity of Biosimilar versus Reference Trastuzumab in Early HER2-Positive Breast Cancer.
Jackson I, Zhang N, Sullivan M, et al.
JACC. CardioOncology 2026; doi:10.1016/j.jaccao.2026.07.009.
PMID: 42720642
12
Usefulness of Left Atrial Remodeling in Predicting CardiacToxicity During Trastuzumab Therapy for Breast Cancer.
Bergamini C, Benfari G, Dolci G, et al.
The American journal of cardiology 2018; (122(5)):885-889 doi:10.1016/j.amjcard.2018.05.022.
PMID: 30053998
13
Cardiac function surveillance practices and outcomes in patients with HER2-positive breast cancer treated with trastuzumab: a retrospective cohort study across a safety-net and tertiary care setting.
Huang L, Manthena P, Su M, et al.
Cardio-oncology (London, England) 2025; (11(1)):74 doi:10.1186/s40959-025-00376-9.
PMID: 40842038
14
Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics.
O'Shaughnessy J, Gradishar W, O'Regan R, Gadi V
Clinical breast cancer 2023; (23(4)):350-362 doi:10.1016/j.clbc.2023.03.007.
PMID: 37149421
15
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer.
Geyer CE, Untch M, Huang CS, et al.
The New England journal of medicine 2025; (392(3)):249-257 doi:10.1056/NEJMoa2406070.
PMID: 39813643
16
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, et al.
The New England journal of medicine 2019; (380(7)):617-628 doi:10.1056/NEJMoa1814017.
PMID: 30516102
17
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline.
Runowicz CD, Leach CR, Henry NL, et al.
CA: a cancer journal for clinicians 2016; (66(1)):43-73 doi:10.3322/caac.21319.
PMID: 26641959
18
Use of posttreatment imaging and biomarkers in survivors of early-stage breast cancer: Inappropriate surveillance or necessary care?
Hahn EE, Tang T, Lee JS, et al.
Cancer 2016; (122(6)):908-16 doi:10.1002/cncr.29811.
PMID: 26650715
19
Follow-up after treatment for breast cancer: Practical guide to survivorship care for family physicians.
Sisler J, Chaput G, Sussman J, Ozokwelu E
Canadian family physician Medecin de famille canadien 2016; (62(10)):805-811.
PMID: 27737976
20
Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review.
Sakai H, Tsurutani J
Translational breast cancer research : a journal focusing on translational research in breast cancer 2026; (7()):28 doi:10.21037/tbcr-25-29.
PMID: 42582644
21
A Vanguard Approach to the Design and Delivery of Nurse-Led Survivorship Care.
Sara SAM, Chambers SK, Briggs R, et al.
Seminars in oncology nursing 2023; (39(1)):151366 doi:10.1016/j.soncn.2022.151366.
PMID: 36411123

This page provides information about survivorship after HER2-positive breast cancer for educational purposes only and does not constitute medical advice. Ask your oncology team about your personal follow-up schedule, symptoms, heart monitoring, and treatment decisions.

Get notified when new evidence is published on HER2 positive breast carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Guide Contents